000128781 001__ 128781
000128781 005__ 20240228143348.0
000128781 0247_ $$2doi$$a10.1111/bjh.14038
000128781 0247_ $$2pmid$$apmid:26991959
000128781 0247_ $$2ISSN$$a0007-1048
000128781 0247_ $$2ISSN$$a1365-2141
000128781 0247_ $$2altmetric$$aaltmetric:6235465
000128781 037__ $$aDKFZ-2017-04796
000128781 041__ $$aeng
000128781 082__ $$a610
000128781 1001_ $$0P:(DE-He78)7ccc574e713526d2a22d7acb9b2248c5$$aHillengass, Jens$$b0$$eFirst author$$udkfz
000128781 245__ $$aIncreased microcirculation detected by dynamic contrast-enhanced magnetic resonance imaging is of prognostic significance in asymptomatic myeloma.
000128781 260__ $$aOxford [u.a.]$$bWiley-Blackwell55962$$c2016
000128781 3367_ $$2DRIVER$$aarticle
000128781 3367_ $$2DataCite$$aOutput Types/Journal article
000128781 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1524745781_17003
000128781 3367_ $$2BibTeX$$aARTICLE
000128781 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000128781 3367_ $$00$$2EndNote$$aJournal Article
000128781 520__ $$aThis prospective study aimed to investigate the prognostic significance of dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) as a non-invasive imaging technique delivering the quantitative parameters amplitude A (reflecting blood volume) and exchange rate constant kep (reflecting vascular permeability) in patients with asymptomatic monoclonal plasma cell diseases. We analysed DCE-MRI parameters in 33 healthy controls and 148 patients with monoclonal gammopathy of undetermined significance (MGUS) or smouldering multiple myeloma (SMM) according to the 2003 IMWG guidelines. All individuals underwent standardized DCE-MRI of the lumbar spine. Regions of interest were drawn manually on T1-weighted images encompassing the bone marrow of each of the 5 lumbar vertebrae sparing the vertebral vessel. Prognostic significance for median of amplitude A (univariate: P < 0·001, hazard ratio (HR) 2·42, multivariate P = 0·02, HR 2·7) and exchange rate constant kep (univariate P = 0·03, HR 1·92, multivariate P = 0·46, HR 1·5) for time to progression of 79 patients with SMM was found. Patients with amplitude A above the optimal cut-off point of 0·89 arbitrary units had a 2-year progression rate into symptomatic disease of 80%. In conclusion, DCE-MRI parameters are of prognostic significance for time to progression in patients with SMM but not in individuals with MGUS.
000128781 536__ $$0G:(DE-HGF)POF3-315$$a315 - Imaging and radiooncology (POF3-315)$$cPOF3-315$$fPOF III$$x0
000128781 588__ $$aDataset connected to CrossRef, PubMed,
000128781 7001_ $$aRitsch, Judith$$b1
000128781 7001_ $$0P:(DE-HGF)0$$aMerz, Maximilian$$b2
000128781 7001_ $$aWagner, Barbara$$b3
000128781 7001_ $$0P:(DE-He78)a9f6104e5c2c26345dcb242e6bdcb2b2$$aKunz, Christina$$b4$$udkfz
000128781 7001_ $$0P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aHielscher, Thomas$$b5$$udkfz
000128781 7001_ $$aLaue, Hendrik$$b6
000128781 7001_ $$aBäuerle, Tobias$$b7
000128781 7001_ $$aZechmann, Christian M$$b8
000128781 7001_ $$aHo, Anthony D$$b9
000128781 7001_ $$0P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec$$aSchlemmer, Heinz-Peter$$b10$$udkfz
000128781 7001_ $$aGoldschmidt, Hartmut$$b11
000128781 7001_ $$aMoehler, Thomas M$$b12
000128781 7001_ $$0P:(DE-He78)3e76653311420a51a5faeb80363bd73e$$aDelorme, Stefan$$b13$$eLast author$$udkfz
000128781 773__ $$0PERI:(DE-600)1475751-5$$a10.1111/bjh.14038$$gVol. 174, no. 1, p. 127 - 135$$n1$$p127 - 135$$tBritish journal of haematology$$v174$$x0007-1048$$y2016
000128781 909CO $$ooai:inrepo02.dkfz.de:128781$$pVDB
000128781 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)7ccc574e713526d2a22d7acb9b2248c5$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000128781 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000128781 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a9f6104e5c2c26345dcb242e6bdcb2b2$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000128781 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000128781 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000128781 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3e76653311420a51a5faeb80363bd73e$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000128781 9131_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000128781 9141_ $$y2016
000128781 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBRIT J HAEMATOL : 2015
000128781 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000128781 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000128781 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000128781 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000128781 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000128781 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000128781 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000128781 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000128781 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000128781 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000128781 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000128781 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000128781 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bBRIT J HAEMATOL : 2015
000128781 9201_ $$0I:(DE-He78)E010-20160331$$kE010$$lRadiologie$$x0
000128781 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x1
000128781 980__ $$ajournal
000128781 980__ $$aVDB
000128781 980__ $$aI:(DE-He78)E010-20160331
000128781 980__ $$aI:(DE-He78)C060-20160331
000128781 980__ $$aUNRESTRICTED